Molecular cytogenetic analysis of 11 new breast cancer cell lines - PubMed (original) (raw)

Molecular cytogenetic analysis of 11 new breast cancer cell lines

F Forozan et al. Br J Cancer. 1999 Dec.

Free PMC article

Abstract

We describe a survey of genetic changes by comparative genomic hybridization (CGH) in 11 human breast cancer cell lines recently established in our laboratory. The most common gains took place at 8q (73%), 1 q (64%), 7q (64%), 3q (45%) and 7p (45%), whereas losses were most frequent at Xp (54%), 8p (45%), 18q (45%) and Xq (45%). Many of the cell lines displayed prominent, localized DNA amplifications by CGH. One-third of these loci affected breast cancer oncogenes, whose amplifications were validated with specific probes: 17q12 (two cell lines with ERBB2 amplifications), 11q13 (two with cyclin-D1), 8p11-p12 (two with FGFR1) and 10q25 (one with FGFR2). Gains and amplifications affecting 8q were the most common genetic alterations in these cell lines with the minimal, common region of involvement at 8q22-q23. No high-level MYC (at 8q24) amplifications were found in any of the cell lines. Two-thirds of the amplification sites took place at loci not associated with established oncogenes, such as 1q41-q43, 7q21-q22, 7q31, 8q23, 9p21-p23, 11p12-p14, 15q12-q14, 16q13-q21, 17q23, 20p11-p12 and 20q13. Several of these locations have not been previously reported and may harbour important genes whose amplification is selected for during cancer development. In summary, this set of breast cancer cell lines displaying prominent DNA amplifications should facilitate discovery and functional analysis of genes and signal transduction pathways contributing to breast cancer development.

PubMed Disclaimer

Similar articles

• Comparative genomic hybridization analysis of breast tumors with predetermined profiles of DNA amplification.
  Courjal F, Theillet C. Courjal F, et al. Cancer Res. 1997 Oct 1;57(19):4368-77. Cancer Res. 1997. PMID: 9331100
• Comparative genomic hybridization analysis of 38 breast cancer cell lines: a basis for interpreting complementary DNA microarray data.
  Forozan F, Mahlamäki EH, Monni O, Chen Y, Veldman R, Jiang Y, Gooden GC, Ethier SP, Kallioniemi A, Kallioniemi OP. Forozan F, et al. Cancer Res. 2000 Aug 15;60(16):4519-25. Cancer Res. 2000. PMID: 10969801
• Genomic DNA-chip hybridization reveals a higher incidence of genomic amplifications in pancreatic cancer than conventional comparative genomic hybridization and leads to the identification of novel candidate genes.
  Holzmann K, Kohlhammer H, Schwaenen C, Wessendorf S, Kestler HA, Schwoerer A, Rau B, Radlwimmer B, Döhner H, Lichter P, Gress T, Bentz M. Holzmann K, et al. Cancer Res. 2004 Jul 1;64(13):4428-33. doi: 10.1158/0008-5472.CAN-04-0431. Cancer Res. 2004. PMID: 15231651
• DNA copy number amplifications in human neoplasms: review of comparative genomic hybridization studies.
  Knuutila S, Björkqvist AM, Autio K, Tarkkanen M, Wolf M, Monni O, Szymanska J, Larramendy ML, Tapper J, Pere H, El-Rifai W, Hemmer S, Wasenius VM, Vidgren V, Zhu Y. Knuutila S, et al. Am J Pathol. 1998 May;152(5):1107-23. Am J Pathol. 1998. PMID: 9588877 Free PMC article. Review.
• Molecular cytogenetics of prostate cancer.
  Nupponen NN, Visakorpi T. Nupponen NN, et al. Microsc Res Tech. 2000 Dec 1;51(5):456-63. doi: 10.1002/1097-0029(20001201)51:5<456::AID-JEMT8>3.0.CO;2-H. Microsc Res Tech. 2000. PMID: 11074616 Review.

Cited by

• Development and implementation of the SUM breast cancer cell line functional genomics knowledge base.
  Ethier SP, Guest ST, Garrett-Mayer E, Armeson K, Wilson RC, Duchinski K, Couch D, Gray JW, Kappler C. Ethier SP, et al. NPJ Breast Cancer. 2020 Jul 21;6:30. doi: 10.1038/s41523-020-0173-z. eCollection 2020. NPJ Breast Cancer. 2020. PMID: 32715085 Free PMC article.
• Evaluation of activity and combination strategies with the microtubule-targeting drug sagopilone in breast cancer cell lines.
  Eschenbrenner J, Winsel S, Hammer S, Sommer A, Mittelstaedt K, Drosch M, Klar U, Sachse C, Hannus M, Seidel M, Weiss B, Merz C, Siemeister G, Hoffmann J. Eschenbrenner J, et al. Front Oncol. 2011 Nov 16;1:44. doi: 10.3389/fonc.2011.00044. eCollection 2011. Front Oncol. 2011. PMID: 22649765 Free PMC article.
• Genomic amplification and oncogenic properties of the GASC1 histone demethylase gene in breast cancer.
  Liu G, Bollig-Fischer A, Kreike B, van de Vijver MJ, Abrams J, Ethier SP, Yang ZQ. Liu G, et al. Oncogene. 2009 Dec 17;28(50):4491-500. doi: 10.1038/onc.2009.297. Epub 2009 Sep 28. Oncogene. 2009. PMID: 19784073 Free PMC article.
• Structure and dynamics of the EGFR/HER2 heterodimer.
  Bai X, Sun P, Wang X, Long C, Liao S, Dang S, Zhuang S, Du Y, Zhang X, Li N, He K, Zhang Z. Bai X, et al. Cell Discov. 2023 Feb 13;9(1):18. doi: 10.1038/s41421-023-00523-5. Cell Discov. 2023. PMID: 36781849 Free PMC article.
• MicroRNAs as possible indicators of drug sensitivity in breast cancer cell lines.
  Uhr K, Prager-van der Smissen WJC, Heine AAJ, Ozturk B, van Jaarsveld MTM, Boersma AWM, Jager A, Wiemer EAC, Smid M, Foekens JA, Martens JWM. Uhr K, et al. PLoS One. 2019 May 7;14(5):e0216400. doi: 10.1371/journal.pone.0216400. eCollection 2019. PLoS One. 2019. PMID: 31063487 Free PMC article.

References

1. 1. Nat Genet. 1994 Oct;8(2):155-61 - PubMed
2. 1. Biochim Biophys Acta. 1994 Dec 30;1198(2-3):113-30 - PubMed
3. 1. J Cell Physiol. 1995 Jun;163(3):589-96 - PubMed
4. 1. Cancer Res. 1995 Nov 15;55(22):5415-23 - PubMed
5. 1. Mol Carcinog. 1996 Mar;15(3):227-38 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Europe PubMed Central
  • Nature Publishing Group
  • PubMed Central

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information

• Research Materials

  • Cellosaurus - a cell line knowledge resource
  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal